Skip to main content

Monday's Health Winners & Losers

Dendreon continues to advance, after Friday's good news from the FDA on its prostate drug.

Updated from 12:58 p.m. EDT



was one of Monday's best performers. On Friday, the Food and Drug Administration said the company's prostate cancer vaccine treatment, Provenge, was safe and effective in treating prostate cancer. A final decision from the FDA is expected on May 15. Shares of Dendreon, which soared 147% on Friday, closed up $1.37, or 10.6%, to $14.30.


(NVAX) - Get Novavax, Inc. Report

jumped 17.8% after the company said its vaccine prevention for H9N2, another strain of the avian flu virus, was effective when tested on animals. Shares of Novavax gained 46 cents to $3.05.

Shares of



were also higher after Jefferies upgraded the stock to buy from hold. The firm also upped Cephalon's stock price target to $88 from $69. The stock climbed $4.75, or 6.7%, to $75.96.

On the other hand,

Bruker BioSciences

(BRKR) - Get Bruker Corporation Report

was losing ground after Bear Stearns lowered its rating on the company to underperform from peer perform. Shares of Bruker were recently down 26 cents, or 2.5%, to $10.26.

Among other health care winners,

TheStreet Recommends


(CELG) - Get Celgene Corporation Report

added 2.6% to $53.80.

MedcoHealth Solutions


was gaining 1.8% to $73.84.


(MRK) - Get Merck & Co., Inc. Report

was higher by 1.9% at $45.01.

Among decliners,

CV Therapeutics


shed 4.5% to $7.62.



was off 2.2% to $35.60, and



was lower by 0.4% at $25.42.